

## Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)

The following resolutions were passed at the annual general meeting (the “AGM”) of Vicore Pharma Holding AB (publ) on 11 May 2022.

### **Adoption of income statement and balance sheet for the financial year 2021 and discharge from liability**

The AGM resolved to adopt the income statement and the consolidated income statement for the financial year 2021 as well as the balance sheet and consolidated balance sheet as of 31 December 2021. The members of the board of directors and the managing director were discharged from liability for the financial year 2021.

### **Allocation of profit or loss**

The AGM resolved, in accordance with the board of directors’ proposal, that no dividend shall be paid for 2021 and that the results of the company shall be carried forward.

### **Election of board members and auditors, and fees to the board of directors and auditors**

The AGM resolved, in accordance with the nomination committee’s proposal, to re-elect Jacob Gunterberg, Heidi Hunter, Maarten Kraan, Sara Malcus and Hans Schikan as members of the board of directors for the period until the end of the next annual general meeting. Jacob Gunterberg was re-elected as the chairman of the board of directors. The audit firm EY AB was re-elected auditor of the company for the period until the end of the next annual general meeting.

The AGM further resolved on directors’ fees, including an additional fee subject to the board members’ acquisition of shares in Vicore Pharma, in accordance with the nomination committee’s proposal. The AGM further resolved, in accordance with the nomination committee’s proposal, that the fee to the auditor shall be paid as per approved statement of costs.

### **Guidelines on remuneration to members of group management**

The AGM resolved, in accordance with the proposal from the board of directors, on guidelines for remuneration to members of group management. In short, the guidelines state that remuneration within Vicore Pharma shall be based on principles of performance, competitiveness and fairness and consist of fixed remuneration, variable remuneration, share and share price-related incentive programs, pension and other benefits. The guidelines do not apply to any remuneration decided or approved by the general meeting. The board of directors has reviewed the description of the company’s business in the remuneration guidelines and made a minor editorial change. No significant changes have been made to the guidelines compared to previously adopted guidelines.

### **Approval of the board of directors’ remuneration report**

The AGM resolved to approve the remuneration report presented by the board of directors.



### **Authorization to issue new shares**

The AGM resolved in accordance with the board of directors' proposal to authorize the board of directors to issue new shares corresponding to not more than 20 per cent of the number of outstanding shares and votes at the time of the AGM.

**CEO presentation for the Annual General Meeting 2022:** <https://tv.streamfabriken.com/vicore-pharma-inspelning-2022>

Gothenburg, 11 May 2022

### **Vicore Pharma Holding AB (publ)**

#### **For further information, please contact:**

Carl-Johan Dalsgaard, CEO

Phone: +46 70 975 98 63

E-mail: [carl-johan.dalsgaard@vicorepharma.com](mailto:carl-johan.dalsgaard@vicorepharma.com)

Hans Jeppsson, CFO

Phone: +46 70 553 14 65

E-mail: [hans.jeppsson@vicorepharma.com](mailto:hans.jeppsson@vicorepharma.com)

**The information was submitted for publication, through the agency of the contact persons set out above, on 11 May 2022 at 10:30 CEST.**

#### **About Vicore Pharma Holding AB (publ)**

*Vicore is a clinical-stage pharmaceutical company focused on developing innovative medicines in severe lung diseases where the Angiotensin II type 2 receptor (AT2R) plays an important role. The company currently has four development programs, VP01, VP02, VP03 and VP04. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF), pulmonary artery hypertension (PAH) and COVID-19. VP02 is a new formulation and delivery route of thalidomide and focuses on the underlying disease and the severe cough associated with IPF. VP03 includes the development of new AT2 receptor agonists. VP04 develops a clinically validated digital therapeutic for IPF patients.*

*The company's shares (VICO) are listed on Nasdaq Stockholm's main market. For more information, see [www.vicorepharma.com](http://www.vicorepharma.com).*